Results 21 to 30 of about 41,943 (257)

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations

Frontiers in Immunology, 2022
Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses
Nicola Principe, Nicola Principe, Nicola Principe, Wayne J. Aston, Danika E. Hope, Caitlin M. Tilsed, Caitlin M. Tilsed, Caitlin M. Tilsed, Scott A. Fisher, Scott A. Fisher, Scott A. Fisher, Louis Boon, Ian M. Dick, Ian M. Dick, Wee Loong Chin, Wee Loong Chin, Wee Loong Chin, Alison M. McDonnell, Anna K. Nowak, Anna K. Nowak, Anna K. Nowak, Richard A. Lake, Richard A. Lake, Richard A. Lake, Jonathan Chee, Jonathan Chee, Jonathan Chee, Willem Joost Lesterhuis, Willem Joost Lesterhuis, Willem Joost Lesterhuis, Willem Joost Lesterhuis   +30 more
doaj   +1 more source

Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice

Nature Communications, 2022
Immune checkpoint blockade (ICB) is partially successful as a cancer therapy. Here using mouse models, the authors transcriptionally monitor responding and non-responding tumours showing that responding tumours were associated with transient IFN-β ...
Rachael M. Zemek, Wee Loong Chin, Vanessa S. Fear, Ben Wylie, Thomas H. Casey, Cath Forbes, Caitlin M. Tilsed, Louis Boon, Belinda B. Guo, Anthony Bosco, Alistair R. R. Forrest, Michael J. Millward, Anna K. Nowak, Richard A. Lake, Timo Lassmann, W. Joost Lesterhuis   +15 more
doaj   +1 more source

A patient with epithelioid pleural mesothelioma (Myxoid variant) who survived for a long period without treatment

Respiratory Medicine Case Reports, 2021
Pleural mesothelioma is a disease with a very poor prognosis. Here, we report a mesothelioma patient who survived for 5 years and a half. As a result of the autopsy, the tumor was diagnosed as a myxoid variant, which is internationally proposed as a ...
Keiichi Mizuhashi, Kenzo Okamoto, Takumi Kishimoto   +2 more
doaj   +1 more source

Non-malignant asbestos-related diseases: a clinical view. [PDF]

Clin Med (Lond), 2014
Fishwick D, Barber CM.
europepmc   +3 more sources

Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model

BMC Research Notes, 2020
Objective There is substantial evidence that exercise can safely reduce the risk of cancer and improve survival in different human cancer populations.
Scott A. Fisher, Carolyn J. Peddle-McIntyre, Kimberley Burton, Robert U.  Newton, Elly Marcq, Richard A. Lake, Anna K. Nowak   +6 more
doaj   +1 more source

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action

Frontiers in Oncology, 2022
Chemotherapy has historically been the mainstay of cancer treatment, but our understanding of what drives a successful therapeutic response remains limited.
Caitlin M. Tilsed, Caitlin M. Tilsed, Scott A. Fisher, Scott A. Fisher, Anna K. Nowak, Anna K. Nowak, Anna K. Nowak, Richard A. Lake, Richard A. Lake, W. Joost Lesterhuis, W. Joost Lesterhuis, W. Joost Lesterhuis   +11 more
doaj   +1 more source

Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?

Frontiers in Oncology, 2021
The success of immunotherapy that targets inhibitory T cell receptors for the treatment of multiple cancers has seen the anti-tumor immune response re-emerge as a promising biomarker of response to therapy. Longitudinal characterization of T cells in the
Nicola Principe, Nicola Principe, Joel Kidman, Joel Kidman, Richard A. Lake, Richard A. Lake, Willem Joost Lesterhuis, Willem Joost Lesterhuis, Anna K. Nowak, Anna K. Nowak, Alison M. McDonnell, Jonathan Chee, Jonathan Chee   +12 more
doaj   +1 more source

Immune marker expression of irradiated mesothelioma cell lines

Frontiers in Oncology, 2022
BackgroundThough immune checkpoint inhibition has recently shown encouraging clinical efficacy in mesothelioma, most patients do not respond. Combining immune checkpoint inhibition with radiotherapy presents an attractive option for improving treatment ...
Faith Chang, Faith Chang, Synat Keam, Synat Keam, Tracy Seymour Hoang, Tracy Seymour Hoang, Jenette Creaney, Jenette Creaney, Suki Gill, Suki Gill, Anna K. Nowak, Anna K. Nowak, Anna K. Nowak, Martin Ebert, Martin Ebert, Alistair M. Cook, Alistair M. Cook   +16 more
doaj   +1 more source

How to Better Understand the Influence of Host Genetics on Developing an Effective Immune Response to Thoracic Cancers

Frontiers in Oncology, 2021
Thoracic cancers pose a significant global health burden. Immune checkpoint blockade therapies have improved treatment outcomes, but durable responses remain limited. Understanding how the host immune system interacts with a developing tumor is essential
Kiarash Behrouzfar, Kiarash Behrouzfar, Kimberley Burton, Kimberley Burton, Steve E. Mutsaers, Steve E. Mutsaers, Grant Morahan, Richard A. Lake, Scott A. Fisher, Scott A. Fisher   +9 more
doaj   +1 more source

A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice

BMC Cancer, 2017
Background Cytotoxic chemotherapeutics form the cornerstone of systemic treatment of many cancers. Patients are dosed at maximum tolerated dose (MTD), which is carefully determined in phase I studies.
Wayne J. Aston, Danika E. Hope, Anna K. Nowak, Bruce W. Robinson, Richard A. Lake, W. Joost Lesterhuis   +5 more
doaj   +1 more source